Monte Rosa Therapeutics, Inc. GLUE
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is an immunology/inflammation drug developer. Its lead program, MRT-6160 (DDY391), is in Phase 2 for Sjögren's disease; psoriatic arthritis. Its next catalyst on record is MRT-8102: GFORCE-2 Phase 2b study initiation in coronary artery disease (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MRT-8102 — GFORCE-2 Phase 2b study initiation in coronary artery disease (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MRT-6160 (DDY391) | Sjögren's disease | small molecule | Phase 2 |
| MRT-6160 (DDY391) | psoriatic arthritis | small molecule | Phase 2 |
| MRT-2359 | metastatic castration-resistant prostate cancer | small molecule | Phase 2 |
| MRT-8102 | coronary artery disease; gout; hidradenitis suppurativa | small molecule | Phase 1 |
| Roche collaboration targets | undisclosed | small molecule | Pre-clinical |
| 2025 Novartis I&I programs (First Licensed Program + 2 Optioned) | immunology & inflammation | small molecule | Pre-clinical |
| CDK2 program | undisclosed | small molecule | Pre-clinical |
| CCNE1 program | undisclosed | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of ASCVD to levels comparable to healthy volunteers across all dose levels, with adverse events comparable to placebo.
Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates comparable to placebo
Filing - started Novartis initiated Phase 2a/b study of MRT-6160 (DDY391) in psoriatic arthritis in October 2026, triggering a $37.5 million milestone payment.
In October, Monte Rosa announced achievement of an additional milestone associated with Novartis initiating a second Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis (PsA).
Filing - started Novartis initiated Phase 2a/b study of MRT-6160 (DDY391) in Sjögren's disease in September 2026, triggering a $50 million milestone payment.
In September, Monte Rosa announced achievement of a milestone associated with its collaborator Novartis initiating a global Phase 2a/b randomized, double-blind, placebo-controlled study (NCT07737743), evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.